Eli Lilly's (LLY) jaypirca significantly continued progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
- BRUIN CLL-322 is the first Phase 3 readout in CLL to utilize and outperform a venetoclax-containing control arm.
Context
Eli Lilly's latest trial results indicate a significant improvement in progression-free survival for their drug Jaypirca when combined with Venetoclax in patients with previously treated CLL/SLL. This Phase 3 readout not only outperforms existing treatments but also suggests potential market momentum for LLY, reinforcing its competitive position in the pharmaceuticals sector. Investors will be keen to assess the implications for future revenue growth and pricing strategies as this could bolster Eli Lilly's profile in oncology.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#ELI LILLY & CO#LLY.US#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ELI LILLY AND CO#LLY#US EQUITIES